AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Amarin Corporation PLC (NASDAQ:AMRN)
13.62 USD
-0.320 2.296%Sponsored Reports
Loading...
| Previous Close (in USD) | 13.94 |
|---|---|
| Change | -0.320 2.296% |
| 52 W H/L (in USD) | 20.900/9.440 |
| EBITDA (in USD) | -10.913M |
| PE Ratio | -- |
| Volume | 54264 |
| Diluted Eps TTM | -1.80 |
| Total Assets (in USD) | 670.775M |
|---|---|
| Total Liabilities (in USD) | 211.494M |
| Revenue TTM (in USD) | 213.646M |
| Cash (in USD) | 134.861M |
| Market Cap (in USD) | 306.624 M |
| Revenue Per Share TTM | 10.297 |
| Gross Profit TTM (in USD) | 120.868M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Employees: 80
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Karim Mikhail | Pres, CEO & Director | 1971 |
| 2. | Dr. Steven B. Ketchum Ph.D. | Pres of R&D, Exec. VP and Chief Scientific Officer | 1965 |
| 3. | Mr. Jason M. Marks J.D. | Exec. VP, Chief Legal and Compliance Officer & Corp. Sec. | 1976 |
| 4. | Mr. Joseph T. Kennedy J.D. | Exec. VP of Strategic Initiatives & Gen. Counsel | 1968 |
| 5. | Mr. Aaron D. Berg | Exec. VP & Pres of U.S. | 1963 |
| 6. | Mr. Thomas Charles Reilly | CFO & Sr. VP | 1972 |
| 7. | Dr. David Keenan | Sr. VP of Technical Operations | NA |
| 8. | Ms. Lisa M. DeFrancesco | Sr. VP of Corp. Affairs & Investor Relations | 1980 |
| 9. | Alina Kolomeyer | Director of Communications | NA |
| 10. | Mr. Jordan Zwick | Sr. VP of Corp. Bus. Devel. | 1987 |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
LLY
Eli Lilly and Company |
-20.120 1.706% | 1179.65 | 78.140 | 31.949 | 16.338 | 45.832 | 16.647 | 54.359 |
|
JNJ
Johnson & Johnson |
-3.340 1.320% | 252.01 | 29.170 | 14.327 | 3.740 | 5.180 | 3.805 | 15.225 |
|
ABBV
AbbVie Inc |
-0.819 0.322% | 253.1 | 86.320 | 14.327 | 5.891 | 50.457 | 7.044 | 24.438 |
|
AZN
AstraZeneca PLC |
-3.675 2.176% | 168.46 | 30.690 | 19.231 | 5.297 | 6.445 | 5.721 | 17.228 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -41.548M | -77.2M | -53.67M | -103.805M | 11.291M |
| Minority Interest | - | - | - | - | - |
| Net Income | -38.798M | -82.183M | -59.112M | -105.803M | 7.729M |
| Selling General Administrative | 115.003M | 72.723M | 88.612M | 118.802M | 141.86M |
| Gross Profit | 120.868M | 81.382M | 165.541M | 242.484M | 461.86M |
| Reconciled Depreciation | 3.028M | 3.013M | 2.992M | 3.096M | 2.857M |
| Ebit | - | -77.194M | -53.662M | -92.343M | 22.28M |
| Ebitda | -41.541M | -74.18M | -50.697M | -90.264M | 25.137M |
| Depreciation And Amortization | - | 3.014M | 2.965M | 2.079M | 2.857M |
| Operating Income | -13.941M | -91.797M | -67.588M | -92.343M | 22.28M |
| Other Operating Expenses | 196.694M | 320.411M | 374.499M | 461.536M | 558.968M |
| Interest Expense | 0.007M | 0.007M | 0.008M | 0.015M | 0.129M |
| Tax Provision | 2.75M | 4.983M | -5.519M | 1.998M | 3.562M |
| Interest Income | 10.853M | 13.403M | 10.016M | 2.819M | 1.22M |
| Net Interest Income | 10.846M | 13.396M | 10.001M | 2.804M | 1.091M |
| Income Tax Expense | -2.75M | 4.983M | 5.442M | 1.998M | 3.562M |
| Total Revenue | 182.753M | 228.614M | 306.911M | 369.193M | 583.187M |
| Total Operating Expenses | 134.809M | 173.179M | 233.129M | 334.827M | 437.641M |
| Cost Of Revenue | 61.885M | 147.232M | 141.37M | 126.709M | 121.327M |
| Total Other Income Expense Net | -27.607M | 14.597M | 13.918M | -11.462M | -10.989M |
| Net Income From Continuing Ops | -38.798M | -82.183M | -52.475M | -105.803M | 7.729M |
| Net Income Applicable To Common Shares | - | - | - | -105.803M | 7.729M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 670.775M | 685.349M | 831.684M | 886.179M | 1068.065M |
| Intangible Assets | 13.365M | 16.389M | 19.304M | 21.78M | 23.547M |
| Other Current Assets | 24.35M | 12.852M | 11.618M | 19.492M | 22.352M |
| Total Liab | 211.494M | 199.173M | 279.587M | 290.846M | 400.966M |
| Total Stockholder Equity | 459.281M | 486.176M | 552.097M | 595.333M | 667.099M |
| Other Current Liab | 149.104M | 139.583M | 204.174M | 192.678M | 45.602M |
| Common Stock | 310.184M | 305.298M | 302.756M | 299.002M | 294.027M |
| Capital Stock | 310.184M | 305.298M | 302.756M | 299.002M | 294.027M |
| Retained Earnings | -1707.344M | -1668.546M | -1586.363M | -1527.251M | -1421.448M |
| Good Will | 13.365M | - | - | - | - |
| Other Assets | - | - | - | 164.078M | 121.71M |
| Cash | 134.861M | 121.038M | 199.777M | 217.666M | 219.454M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 194.459M | 179.949M | 259.277M | 259.479M | 370.682M |
| Current Deferred Revenue | - | - | 2.341M | 2.199M | 2.649M |
| Net Debt | -122.701M | -113.315M | -191.04M | -207.651M | -210.878M |
| Short Term Debt | - | - | - | - | 207.509M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 12.16M | 7.723M | 8.737M | 10.015M | 8.576M |
| Other Stockholder Equity | 1856.441M | 1849.424M | 1835.704M | 1823.582M | 1794.52M |
| Property Plant Equipment | - | - | - | 9.948M | 9.085M |
| Total Current Assets | 649.882M | 595.399M | 724.981M | 689.098M | 878.727M |
| Long Term Investments | - | - | 0M | 1.275M | 34.996M |
| Short Term Investments | 167.929M | 173.182M | 121.407M | 91.695M | 234.674M |
| Net Receivables | 126.832M | 122.279M | 133.563M | 130.99M | 163.653M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 195.91M | 166.048M | 258.616M | 228.732M | 234.676M |
| Accounts Payable | 45.355M | 40.366M | 52.762M | 64.602M | 114.922M |
| Accumulated Other Comprehensive Income | - | - | 0M | - | - |
| Non Currrent Assets Other | 1.055M | 65.953M | 78.975M | 164.078M | 121.71M |
| Non Current Assets Total | 20.893M | 89.95M | 106.703M | 197.081M | 189.338M |
| Capital Lease Obligations | 6.08M | 7.723M | 8.737M | 10.015M | 8.576M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 8.829M | -45.976M | 17.658M | 175.288M | 104.099M |
| Total Cashflows From Investing Activities | 8.85M | -45.976M | -25.621M | 175.288M | 104.103M |
| Total Cash From Financing Activities | -2.039M | -1.443M | 0.231M | -0.379M | -5.073M |
| Net Income | -38.798M | -82.183M | -59.341M | -105.803M | 7.729M |
| Change In Cash | 13.523M | -78.439M | -18.412M | -5.183M | 32.493M |
| Begin Period Cash Flow | 121.338M | 199.777M | 218.189M | 223.372M | 190.879M |
| End Period Cash Flow | 134.861M | 121.338M | 199.777M | 218.189M | 223.372M |
| Total Cash From Operating Activities | 6.744M | -31.02M | 6.907M | -180.092M | -66.537M |
| Depreciation | 3.028M | 3.013M | 2.976M | 3.096M | 2.857M |
| Other Cashflows From Investing Activities | 0.009M | -45.976M | 190.11M | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | 34.96M | 105.443M | 56.339M | -36.422M | -167.066M |
| Sale Purchase Of Stock | - | - | -1.982M | 0.605M | 1.65M |
| Other Cashflows From Financing Activities | -2.179M | -1.574M | -1.99M | -1.044M | -5.073M |
| Capital Expenditures | 0M | 0M | 0.024M | 0.599M | 0M |
| Change In Working Capital | 32.282M | 36.174M | 51.275M | -104.071M | -115.99M |
| Other Non Cash Items | -25.539M | -5.729M | 11.996M | 0.473M | 1.929M |
| Free Cash Flow | 6.744M | -31.02M | 6.883M | -180.691M | -66.537M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Nasdaq Composite Index | 4 months ago | 11771 |
| 2. | Voya Multi-Manager International Sm Cp A | 5 months ago | 10540 |
| 3. | Nomura Healthcare Fund Class I | 4 months ago | 9500 |
| 4. | Hector SICAV FIDE Growth | 6 months ago | 3250 |
| 5. | AXA IM Global Small Cap Eq QI A(US$) | 1 year ago | 61937 |
| 6. | China Universal NASDAQ Bio-Tch ETF(QDII) | 2 years ago | 46967 |
| 7. | Blackstone Alternative Multi-Strategy I | 2 years ago | 44700 |
| 8. | ProShares Ultra Nasdaq Biotechnology | 1 year ago | 22433 |
| 9. | Old Westbury Small & Mid Cap Strategies | 5 months ago | 55730 |
| 10. | Waterfront OS | 9 months ago | 53772 |
| 11. | Waterfront OE | 9 months ago | 37748 |
| 12. | State Street® SPDR® Ptf Dev Wld exUS ETF | 3 months ago | 16660 |
| 13. | SEI International Equity F (SIT) | 3 months ago | 13654 |
| 14. | State Street® SPDR® S&P® Intl Sm Cp ETF | 3 months ago | 7824 |
| 15. | Steward Values Enhanced International I | 3 months ago | 5897 |
| 16. | Acadian European SmCp Eq C2-i-0.7500-EUR | 3 months ago | 5141 |
| 17. | AVIP BlackRock Advtg Small Cp Gr Prtfl | 6 months ago | 855 |
| 18. | Blackstone Alternative Multi-Strategy I | 9 months ago | 685 |
| 19. | ST Dorsey Wright® Intl Momntm Tr 40 CA | 3 months ago | 100 |
| 20. | ST Dorsey Wright® Intl Momntm Tr 41 CA | 3 months ago | 100 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Sarissa Capital Management LP | 6 months ago | 1673395 |
| 2. | Kynam Capital Management, LP | 6 months ago | 389273 |
| 3. | Morgan Stanley - Brokerage Accounts | 9 months ago | 269663 |
| 4. | Eversept Partners, LP | 6 months ago | 172188 |
| 5. | Citadel Advisors Llc | 6 months ago | 168004 |
| 6. | Millennium Management LLC | 6 months ago | 166235 |
| 7. | Waterfront Wealth Inc. | 6 months ago | 142540 |
| 8. | Two Sigma Investments LLC | 6 months ago | 111168 |
| 9. | BNP Paribas Arbitrage, SA | 6 months ago | 104345 |
| 10. | SCP Investment, LP | 6 months ago | 100000 |
| 11. | Susquehanna International Group, LLP | 6 months ago | 61847 |
| 12. | JPMorgan Chase & Co | 9 months ago | 43508 |
| 13. | LCM Capital Management, Inc | 6 months ago | 42262 |
| 14. | Two Sigma Advisers, LLC | 6 months ago | 36995 |
| 15. | Point72 Asset Management, L.P. | 6 months ago | 36491 |
| 16. | Jane Street Group LLC | 6 months ago | 32832 |
| 17. | SEI Investments Co | 9 months ago | 29212 |
| 18. | Jump Financial LLC | 6 months ago | 26900 |
| 19. | Hayek Kallen Investment Management | 6 months ago | 25821 |
| 20. | Advisor Group Holdings, Inc. | 6 months ago | 24271 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...